2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

5432 SWOG S2207: Randomized phase II study of the addition of targeted agents to tafasitamab-lenalidomide in transplant ineligible patients with relapsed/refractory LBCL

Jennifer Effie Amengual, MD, Patrick M Reagan, MD2, Hongli Li, MS3, Joseph M Unger, PhD, MS4, Alexey V. Danilov, MD, PhD5, Michael LeBlanc, PhD6, Tareq Al Baghdadi, MD7, Tricia Hernandez8, Akil Merchant I, MD9, Adolfo Diaz Duque, MD, MSc10, Suparna Mantha, MD11, Jonathan W. Friedberg, MD12, Sonali Smith, MD, FASCO13
1 Columbia University Irving Medical Center, New York, New York, United States
2 University of Rochester, Rochester, New York, United States
3 Fred Hutch Cancer Center, Seattle, Washington, United States
4 Fred Hutch Cancer Center, Seattle, Washington, United States
5 City of Hope, Valencia, California, United States
6 Fred Hutch Cancer Center, Seattle, Washington, United States
7 IHA Extended Care Services, Ypsilanti, Michigan, United States
8 Blood Cancer United - New Jersey, Cranford, New Jersey, United States
9 Cedars Sinai, Los Angeles, California, United States
10 UT Health San Antonio Long (Main) Campus, San Antonio, Texas, United States
11 Rush Copley Medical Center, Aurora, Illinois, United States
12 University of Rochester, Rochester, New York, United States
13 University of Chicago, Chicago, Illinois, United States

Large B-cell lymphoma (LBCL) is the most common lymphoma worldwide. About 40% of patients relapse, and most are not eligible for stem cell transplantation due to chemoresistant disease, advanced age, comorbidities, or lack of access to tertiary care. Similarly, CAR T and bispecifics remain inaccessible for many due to poor fitness, clinically aggressive disease, lack of social support, or nearby tertiary care center. For those with access to CAR T, only a minority of patients derive long term benefit. Thus, R/R LBCL remains an area of great unmet need, with median survival measuring less than one year. Recently, several less intensive regimens designed for outpatient administration have been approved in the United States. Tafasitamab-lenalidomide (tafa-len) is an FDA-approved regimen, with durable remissions in R/R LBCL comparable to those seen with CAR T-cell therapy in some analyses. We hypothesize that the addition of targeted agents to the tafa-len backbone will lead to improved outcomes without added toxicity. The SWOG S2207 trial (NCT05890352) was designed to test the addition of tazemetostat (TAZ, Arm 1) or zanubrutinib (ZANU, Arm 3) to the tafa-len backbone (control, Arm 2) in a randomized study open nationwide. Furthermore, we will evaluate the impact of cell-of-origin (COO) on efficacy.

Following enrollment to the safety run-in (n=39), TAZ was voluntarily withdrawn from the market due to toxicity signals in an unrelated clinical study, therefore Arm 1 has been permanently discontinued. The RP2D for ZANU (Arm 3) was determined at 80mg PO BID with len 20 mg PO daily days 1-21 and standard dose and schedule of tafa 12 mg/kg IV. The randomized Phase II study will proceed and is planned to enroll 120 patients in a 1:1 fashion to Arm 2: tafa-len (25mg) (control); or Arm 3: tafa-len (20mg) + ZANU on a 28-day cycle for up to 13 cycles. Tafa-len will be administered per package insert. The primary objective of the phase II portion is to compare the PFS of patients treated on the experimental arm with the control arm. With a sample size of 120 eligible patients, and n=60 per arm, using a one-sided stratified 1- log-rank test, the study has 90% power to detect a hazard ratio of 1.75. This corresponds to an improvement 1-year PFS from 42% to 60.5%. Secondary objectives will include estimates of hazard ratios for PFS based on GCB and non-GCB subtypes. Exploratory objectives will include exploring PFS by molecular profile and genetic subtypes. Frailty and its correlation to outcome will be assessed by the Cumulative Illness Rating Scale and the timed up and go test. In addition, patient-reported lymphoma specific symptoms by PRO-CTCAE will be measured, as well as quality of life using the FACT-Lym, and will be compared between arms.

Eligibility will allow for patients to have histologically confirmed R/R LBCL as defined by WHO guidelines, FL grade 3B, transformed lymphoma, and HGBCL with/without MYC, BCL2 and/or BCL6 rearrangements. Patients must have COO determination by Hans algorithm. Patients must not be a candidate for or have declined transplant. Those who have disease progression following transplant or CAR T are eligible. Disease assessment with PET-CT or contrast enhanced CT, and patient reported outcomes will occur at baseline and by cycle 3, 6 and EOT. The goal of the SWOG S2207 study is to improve outcomes of patients with R/R LBCL who are not candidates for transplant with targeted, well tolerated therapy.

Funding: NIH/NCI/NCTN grants U10CA180888 and U10CA180819; additional support provided by BeOne Medicines USA, Inc.; Incyte Corporation; and Epizyme Inc., an Ipsen Company.

Jennifer Effie Amengual, MD: AstraZeneca - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)